About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, December 29th, 2014

The QualityStocks
Daily Stock List


VG Life Sciences, Inc. (VGLS)

PennyStocks24, Whisper from Wall Street, Greenbackers, OtcWizard, Smart Penny Stocks, Alist Stocks, Wall Street Wolves, The Bull Report, VIP STOCK ALERTS, HEROSTOCKS, Stockhunter.us, Stock Brain, Liquid Pennies, Atomic Trades, and The Stock Analyzer reported previously on VG Life Sciences, Inc. (VGLS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

A biotechnology company, VG Life Sciences, Inc. concentrates on discovering and developing drug therapies for cancer, infectious disease, and inflammatory, autoimmune disorders. Founded in 1995, the Company is researching two core technologies. One is Targeted Peptide Technology, or TPT, which is currently its primary focus. The other is Metabolic Disruption Technology, or MDT, which is its secondary focus.

VG Life Sciences lists on the OTCQB and it is based in Santa Barbara, California. The Company previously went by the name Viral Genetics, Inc. It changed its corporate name to VG Life Sciences, Inc. in November of 2012. A drug discovery and development enterprise, the Company controls more than 40 US and international patents and pending patents protecting its exclusive biotechnology platform technologies.

VG Life Sciences’ research and development programs are based on technology, which Dr. M. Karen Newell Rogers developed while working at the University of Colorado, the University of Vermont, and Texas A&M University. VG holds the exclusive license to this technology. In addition, the Company has collaborated with many scientists and clinicians at universities across the nation. This includes Stanford University, Harvard University, as well as the Scott & White Healthcare Center, where VG tests TPT in inflammatory disease applications in which it believes TPT could have a benefit.

The Company’s Physician's Investigational New Drug, or P-IND, Phase I clinical trial on late-stage patients with solid tumors is entering its fourth cohort with maximum dosing. It is completing the analysis of the results of those trials. The design of this trial is to assess the safety of a combination treatment using hydroxychloroquine, or HCQ, and a cancer drug sorafenib, which is presently marketed as Nexavar™. The design of the combination treatment is to disrupt the metabolism of the cancer cells, making them more prone to the effects of sorafenib.

Moreover, VG Life Sciences contracted ITR Canada, Inc. in October of 2013 to conduct IND-enabling animal safety studies with its patented peptide VG1177. VG now expects these studies to conclude in early 2015. These animal safety studies are the next important step to move toward clinical trials.

This past October, VG Life Sciences announced that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional neural damage by way of the immune system. The data generated by Dr. Tobin shows immune therapy using VG Life Sciences' patented drug VG1177 can improve the condition.

VG Life Sciences, Inc. (VGLS), closed Monday's trading session at $0.076, down 15.56%, on 154,108 volume with 18 trades. The average volume for the last 60 days is 57,866 and the stock's 52-week low/high is $0.0425/$0.30.

SANUWAVE Health, Inc. (SNWV)

PennyStocks24, RedChip, and SmallCapVoice reported earlier on SANUWAVE Health, Inc. (SNWV), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Alpharetta, Georgia headquartered SANUWAVE Health, Inc. is a shock wave technology company with around 170 devices in use internationally. The Company concentrates on the development and commercialization of patented non-invasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE Health’s shares trade on the OTC Bulletin Board.

The Company’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses. This produces new vascularization and microcirculatory improvement. This assists in restoring the body's normal healing processes and leads to regeneration of tissue.

SANUWAVE Health researches, designs, manufactures, markets and services its products worldwide. There are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses. This includes energy, water, food and industrial markets. Its plan is to apply its Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic/spine, plastic/cosmetic, as well as cardiac conditions.

SANUWAVE's lead product candidate for the global wound care market, dermaPACE®, is CE marked across Europe. It has Canada, Australia, and New Zealand device license approval for the treatment of the skin and subcutaneous soft tissue. In the U.S., dermaPACE is now under the Food and Drug Administration's (FDA's) Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers.

SANUWAVE’s belief is that it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, and stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment via the use of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific.

This past September, SANUWAVE Health announced that the independent Data Monitoring Committee (DMC) performed an interim analysis on the efficacy results for the first 90 patients in the Phase III supplemental clinical trial using the dermaPACE® for treating diabetic foot ulcers. The DMC recommended SANUWAVE continue enrollment of patients into the study up to the next predefined patient analysis point of 130 patients

This month, SANUWAVE announced that it enrolled its 130th patient in the Phase III supplemental clinical trial using dermaPACE® for treating diabetic foot ulcers (DFU's), which represents the number of patients it must enroll for the second interim analysis by the independent Data Monitoring Committee (DMC). SANUWAVE has suspended further enrollment in the study until the Data Monitoring Committee provides feedback on the 130 patients.

Furthermore, this month, the Company announced that is signed a Memoranda of Understanding (MOU) with Dasman Diabetes Institute and Kuwait Life Sciences Company (KLSC) to establish a strategic alliance and joint venture, which will introduce SANUWAVE's dermaPACE® device as a preferred treatment for diabetic foot ulcers in the six nation Gulf Cooperation Council (GCC). KLSC is a wholly owned subsidiary of the National Technology Enterprises Company (NTEC). SANUWAVE has received an initial order for dermaPACE devices that will be used by the Dasman Diabetes Institute to treat diabetic foot ulcers in its state-of-the-art diabetes center in Kuwait.

SANUWAVE Health, Inc. (SNWV), closed Monday's trading session at $0.145, up 11.54%, on 437,492 volume with 63 trades. The average volume for the last 60 days is 363,280 and the stock's 52-week low/high is $0.042/$0.81.

Millennium HealthCare, Inc. (MHCC)

PennyStocks24, Stock Onion, Planet Penny Stocks, Buzz Stocks, PennyStockProphet, SecretStockPromo, Penny Pick Finders, TheMicrocapNews, and SmallCapVoice reported earlier on Millennium HealthCare, Inc. (MHCC), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Millennium HealthCare, Inc., through its wholly owned operating subsidiaries, provides primary care physician practices, physician groups, and healthcare facilities of all sizes with front-line medical devices focused mainly on preventive care through early detection. The Company operates in three segments: Coding, Device, and Vascular. Millennium Medical Devices (MMD) is a wholly-owned subsidiary of Millennium Healthcare.  Millennium HealthCare has its corporate head office in Garden City, New York. The Company’s shares trade on the OTC Markets’ OTCQB.

Millennium HealthCare purchases, supplies, and distributes innovative medical devices and equipment with an emphasis on prevention and early detection. The Company also provides physician practice development, support, and administration services for physician facilities and practices principally for vascular disorders, including peripheral arterial disease of the lower extremities. Moreover, Millennium offers support and services specializing in medical procedure billing and collections, medical procedure coding, call and message management, as well as emergency dispatch.  

Its subsidiary, MMD, signed an exclusive agreement with CDx Diagnostics for distribution of DermCDx™, a brush biopsy test kit used to confirm suspected basal cell carcinoma (BCC).  DermCDx is a minimally invasive test. It combines a patented brush biopsy sampling instrument with computer-assisted three dimensional laboratory analysis.

Millennium HealthCare, through MMD, has an exclusive agreement with CDx Diagnostics to distribute its OralCDx brush biopsy test kit. OralCDx is a non-invasive test used to test dysplasia (the small white and red tissue spots commonly found in the mouth) to rule out precancerous change. The test has previously been available to dentists across the nation. By way of this exclusive collaboration, Primary Care Physicians will be able to administer this test to their patients.

The design of the Company’s VasoScan™ is to analyze Autonomic Nervous System (ANS) function, Stress, and Peripheral Blood Circulation. It provides objective data to assist in assessing disorders, including depression, anxiety, sleep disorder, poor concentration, mental/physical stress degree, chronic fatigue, and blood circulation.

Earlier this month, Millennium Healthcare announced the expansion of its executive management team with the appointment of Mr. Paul Antogiovanni as Senior Vice President of oncology products. Mr. Antogiovanni is a veteran of the pharmaceutical and biotechnology industry. From 1998 to 2014 he has held many positions of increasing responsibility within sales and management, chiefly in oncology. Mr. Antogiovanni is responsible for Millennium HealthCare’s commercial activities including expanding sales channels and vetting new products to acquire.

Millennium HealthCare, Inc. (MHCC), closed Monday's trading session at $0.145, down 3.33%, on 248,100 volume with 27 trades. The average volume for the last 60 days is 520,159 and the stock's 52-week low/high is $0.13/$1.50.

GlyEco, Inc. (GLYE)

RedChip, PennyStocks24, and Greenbackers reported on GlyEco, Inc. (GLYE), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

GlyEco, Inc. is a sustainable glycol technologies leader whose shares trade on the OTC Markets’ OTCQB. The Company is a green chemistry business with a patent-pending technology for transforming hazardous waste into green products. The technology enables its clients to handle the removal of waste glycol in a responsible and environmentally safe manner. GlyEco has its head office in Phoenix, Arizona.

GlyEco Technology™ has the unique ability to clean the polluted glycols from all five waste-producing industries. These industries are HVAC (heating, ventilation, and air conditioning), Textiles, Automotive, Airline, and Medical. The technology recycles waste glycol to meet ASTM Type 1 specifications. This is the same level of purity expected of refinery-grade glycols.

Accordingly, the Company’s clients can treat glycols as a more sustainable resource, recycling and re-using waste glycols continually. The GlyEco Technology™ solution gives the Company’s clients a method to reduce waste while caring for the environment, and while lessening their costs. GlyEco’s technology removes pollutants such as organic acids, esters, as well as high dissolved solids.

The Company announced in 2014 that it started its second phase of expansion at its New Jersey processing center. This is to meet growing customer demand for its refinery-grade recycled glycol. The upgrades will further expand its waste glycol processing capacity and storage capabilities.

This past July, GlyEco announced that it is expanding service in the automotive fluids supply market from its upgraded Landover, Maryland processing center. GlyEco completed substantial storage capacity and throughput upgrades earlier this year to facilitate this growth program.  The Maryland processing center is its second highest-volume facility.

This month, GlyEco announced that it completed the installation of a new proprietary distillation system at its South Carolina Processing Center. This increases capacity by 300 percent. The new technology installation at this processing center considerably improves throughput with minimal impact to production time and costs. Moreover, GlyEco announced in October that it completed the initial build-out of its testing laboratory at its New Jersey Processing Center. Its intention is to offer chemical testing services to external customers in 2015.

Recently, GlyEco announced that its shareholders elected a new board member, Mr. David Ide, at GlyEco’s annual shareholder meeting in Phoenix, Arizona, on October 24, 2014. Mr. Ide brings a wide-spectrum of capabilities to the GlyEco board, as a successful technology entrepreneur and an experienced Chief Executive Officer, Chairman, patented inventor, and Director.

GlyEco, Inc. (GLYE), closed Monday's trading session at $0.39, even for the day, on 26,658 volume with 10 trades. The average volume for the last 60 days is 49,703 and the stock's 52-week low/high is $0.27/$1.22.

MediJane Holdings, Inc. (MJMD)

Wall Street Wolves, Smart Penny Stocks, Pumps and Dumps. Investopedia, The Trading Report, The Stock Enthusiast, Flagler Financial Group, SmallCap Fortunes, Wyatt Investment Research, StockBlogs, StreetAuthority Financial, Trade of the Week, Uncommon Investor, and Insider Wealth Alert reported on MediJane Holdings, Inc. (MJMD), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, MediJane Holdings, Inc. markets and distributes products within the medical marijuana industry. This includes transdermal patches, capsules, sublingual sprays, oral strips, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals. The design of MediJane’s products are to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane Holdings has its corporate headquarters in Longmont, Colorado.

The Company entered into a License Agreement on March 21, 2014, with Phoenix Bio Pharmaceuticals. Phoenix is a Colorado-based developer of medical cannabinoid products and delivery systems for the treatment and management of illnesses. With this License Agreement, MediJane Holdings acquired an exclusive North American license for all intellectual property (IP), processes, and expertise related to certain medicinal cannabinoid products and delivery systems developed by Phoenix Bio Pharmaceuticals.

The licensing agreement extends to additional products or active ingredients sourced by Phoenix through its affiliates and third party suppliers and licensors. Furthermore, MediJane Holdings will have the right to sublicense the rights and to use Phoenix Bio Pharmaceuticals’ copyrights for marketing and distribution purposes.

Its products include the non-drowsy "Daytime Pain plus CBD" oral capsule, the CannaMist cannabinoid spray, and the MediStrip Relaxation oral strips. These have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These are smokeless alternatives. They provide accurate dosages and are part of MediJane’s launch into the chronic pain management market. Concerning the MediStrip Relaxation tongue strip, this product enables the licensed patient to discretely manage their condition as recommended by their doctor.
MediJane Holdings announced in July 2014 that it completed the final formulation of its new Canna Liniment product line of topical analgesics. Canna Liniment is formulated for chronic pain and muscle soreness. It will give pain sufferers another unique cannabinoid delivery system option. The Canna Liniment product is a Chinese-style liniment. It is made with cannabis oil, wintergreen essential oil, as well as menthol.

MediJane Holdings announced this past September that further to its California expansion plan and launch of its MediStrips product line, the Company announced that "MediStrips" are available for sale at Medical cannabis dispensaries in the Sacramento, California region. In addition, in September, it announced that it closed an equity investment of $600,000 via the investment banking firm of Moody Capital Solutions, Inc., a FINRA/SIPC member. The investment capital will be used to assist MediJane in accelerating its California sales strategy with a focus to realize maximum penetration in the largest and still rapidly growing market.

MediJane Holdings, Inc. (MJMD), closed Monday's trading session at $0.0179, up 7.83%, on 113,085 volume with 21 trades. The average volume for the last 60 days is 159,040 and the stock's 52-week low/high is $0.001/$1.60.

Hinto Energy, Inc. (HENI)

SmallCapVoice, Pumps and Dumps, Otcstockexchange, and Whisper from Wall Street reported earlier on Hinto Energy, Inc. (HENI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets’ OTCQB, Hinto Energy, Inc. engages in the exploration, acquisition, and development of oil and natural gas properties in the Rocky Mountain Basins. It has current producing properties in Utah and Montana. The Company is also working to acquire producing oil and natural gas properties, which offer long term production opportunities and proven oil and natural gas reserves. Its first acquisitions are primarily focused on the Uinta Basin of the State of Utah.  Hinto Energy has its corporate headquarters in Greenwood Village, Colorado.

The Company employs state-of-the-art technology for reservoir characterization, to discover by-passed reserves, as well as to evaluate unexploited resources made available with modern horizontal drilling. The technology it employs includes detailed petrophysical analysis, seismic interpretation and high-end geophysical analysis, shale evaluation, and also 3D geological modeling.

Hinto Energy has acquired interests in around 5,700 gross and 4,900 net acres in the Natural Buttes area of Utah through farm out, with an additional potential farm out of up to 5,000 additional acres covering Dakota, Frontier, the Mancos formations, and Cedar Mountain in the Central part of the Uinta Basin, at Natural Buttes. Zones above 9,800 feet are excluded in its farm out. The overall targets will be zones from 9,800 feet to 16,000 feet.

Furthermore, Hinto Energy has acquired 9,200 gross and 9,000 net acres in the Cisco area of Utah. The properties have 35 wells, with 7 producing oil and the rest pending a connection to a gas pipeline or production evaluation.  Presently, the property is producing from 5 to 15 barrels per day.

In addition, Hinto acquired (in June 2013,) a 95 percent working interest (WI) in 6 wells and approximately 1,160 gross leased acres in the Mason Lakes oil field in Musselshell, Montana. In August 2014, Hinto Energy announced the acquisition of a 100 percent WI in 8 oil wells and 640 acres in Musselshell County, Montana.

Hinto Energy announced (this past October) an agreement to take a 75 percent interest in an exploratory well to be drilled in Medina County, Ohio. Medina County is situated on the Appalachian geosyncline. The Company will keep a 75 percent non-operated interest in this initial well and any future wells developed on this property. Moreover, Hinto established a 36 square mile AMI (Area of Mutual Interest) with the operator. This could provide for additional drilling opportunities.

Last week, Hinto Energy announced it drilled a new well in Ohio, situated on the Appalachian geosyncline that includes the Berea Sands and the Ohio shale stratigraphic levels. Hinto is considering the use of 3D seismic to target higher value prospects.

Hinto Energy, Inc. (HENI), closed Monday's trading session at $0.39, even for the day, on 81,475 volume with 5 trades. The average volume for the last 60 days is 8,121 and the stock's 52-week low/high is $0.2501/$0.82.

Evans & Sutherland Computer Corp. (ESCC)

Zacks, MicrocapVoice, Penny Stock Rumble, PennyStockCrowd, Penny Stocks Profile, and OTC Picks reported earlier on Evans & Sutherland Computer Corp. (ESCC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Evans & Sutherland Computer Corp. is the world's first computer graphics company and has developed advanced computer graphics technologies for nearly 40 years. The Company was established in 1968 by Dr. David Evans and Dr. Ivan Sutherland, computer science professors at the University of Utah in Salt Lake City.  Spitz (Domes and Architectural Structures) is a wholly owned subsidiary of Evans & Sutherland.  Spitz is based in Chadds Ford, Pennsylvania. Evans & Sutherland is headquartered in Salt Lake City, Utah.

The Company focuses chiefly on digital planetariums and digital cinemas around the world. It offers Digistar, which is the world's leading digital planetarium system. Additionally, it offers fulldome programs and production services, giant screen films formatted for fulldome theaters, premium-quality projection domes, and theater design services.

Pertaining to Digistar, it is the world's best-selling and most advanced fulldome digital theater system. The design of Digistar is for maximum ease-of-use and intuitive system operation. It features a sophisticated user interface, enhanced realtime capabilities, ultra-high resolution fulldome video playback, as well as open architecture.

Digistar emphasizes flexible storytelling tools to customize presentations to any audience. Evans & Sutherland offers Digistar 5 for creating real time shows. The Company continues to support and maintain all its Digistar systems: Digistar I, Digistar II, Digistar 3, and Digistar 4.

Evans & Sutherland’s Spitz subsidiary offers three types of domes: Standard Lap Seam, Premium Seam™ Dome, and NanoSeam™ Dome. In addition, the Company offers Digital Theater Audio & Lighting. It offers professional theater audio and lighting to provide total, integrated solutions for planetariums and digital fulldome theaters.  

Furthermore, the Company offers Speciality Products that include its laser video projection system for Digistar 4 fulldome theaters. It uses proprietary continuous wave lasers, which utilize technology common to telecommunications systems. Additionally, Evans & Sutherland offers its E&S Digistar 4 Spherical Theater. It, in concert with GOTO, Inc., designed in 2005, the world's first completely spherical theater with 360° seamless projection on the interior.

Evans & Sutherland Computer Corp. (ESCC), closed Monday's trading session at $0.44, down 2.22%, on 9,857 volume with 5 trades. The average volume for the last 60 days is 6,444 and the stock's 52-week low/high is $0.10/$0.715.


The QualityStocks
Company Corner


One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0015, up 15.38%, on 2,660,801 volume with 19 trades. The stock’s average daily volume over the past 60 days is 3,082,768, and its 52-week low/high is $0.0011/$1.00.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

One World Holdings' Prettie Girls! Dolls Make National TV Debut on Popular Fox Daytime Talk Show, "The Real"

The One World Doll Project Announces First Order From Walmart

The One World Doll Project Announces Financing Relationship With New York Hedge Fund, Blackbridge Capital

Mobile Lads Corp. (MOBO)

The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.154, up 14.07%, on 16,250 volume with 8 trades. The stock’s average daily volume over the past 60 days is 54,921, and its 52-week low/high is $0.12/$0.42.

Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.

xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.

xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.

The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.

Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer

Mobile Lads Corp. Company Blog

Mobile Lads Corp. News:

Mobile Lads to Launch CouBox, a Next-Generation Mobile Coupon Application

Mobile Lads Acquires Innovative Online Coupon Platform, CouBox

Mobile Lads Signs Reseller Agreement With Smart Mobile Rewards

Falcon Crest Energy (FCEN)

The QualityStocks Daily Newsletter would like to spotlight Falcon Crest Energy (FCEN). Today, Falcon Crest Energy closed trading at $0.0185, up 8.82%, on 7,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 19,651, and its 52-week low/high is $0.0005/$0.095.

Falcon Crest Energy (FCEN) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Falcon Crest Energy aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Falcon Crest Energy has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Falcon Crest Energy is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Falcon Crest Energy Company Blog

Falcon Crest Energy News:

Falcon Crest Energy Optimistic About Prospecting in Powder River Basin

Falcon Crest Names Michael Cvetanovic to Advisory Council

Falcon Crest Energy Announces Powder River Basin Leasehold Acquisition

Cannabics Pharmaceuticals, Inc. (CNBX)

The QualityStocks Daily Newsletter would like to spotlight Cannabics Pharmaceuticals, Inc. (CNBX). Today, Cannabics Pharmaceuticals, Inc. closed trading at $0.25, up 4.17%, on 5,500 volume with 2 trades. The stock’s average daily volume over the past 60 days is 4,706, and its 52-week low/high is $0.03/$1.40.

Cannabics Pharmaceuticals, Inc. (CNBX) was founded in 2012 by a team of experts in the fields of molecular biology, cancer research and pharmacology, who recognized the potential of cannabinoid-based therapies for debilitating and incurable ailments. Through the course of its research, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for patients wishing to utilize the unique medical properties of the cannabis plant.

Leveraging this expertise and knowledge, Cannabics Pharmaceuticals has created a wide range of solutions for standardized, reproducible and easily administered medical cannabis therapies. The company’s flagship product, Cannabics SR, contains a pure concentrate of cannabinoids derived from select cannabis strains, embedded in a sophisticated formulation which provides beneficial therapeutic effects for 10-12 hours upon a single oral administration.

The excipients of the proprietary Cannabics SR formulation are all certified food-grade ingredients and are free of artificial additives or chemical substances. Cannabics’ proprietary technologies are developed in certified laboratories and are licensed to certified manufacturers and distributors with adequate licenses in their local territories. Cannabics Pharmaceuticals itself does not manufacture, distribute, dispense or possess any controlled substances, including cannabis and cannabis-based preparations.

Co-founders Dr. Zohar Koren (CEO) and Dr. Eyal Ballan (CTO) guide the company’s operations with vast experience in business and pharmaceutical development, strategic consulting, venture capital, evolutionary and environmental sciences, anti-cancer drug development and molecular biology. Under their leadership, Cannabics Pharmaceuticals continues to develop its genetic and phenotipic database to provide superior treatments for incapacitating ailments for which there is no cure. Disclaimer

Cannabics Pharmaceuticals, Inc. Company Blog

Cannabics Pharmaceuticals, Inc. News:

Cannabics Pharmaceuticals engages with Mountain High Products in Colorado

Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain

Cannabics Pharmaceuticals, Inc. (CNBX) Receives Cannabinoid R&D Lab Certification in Israel

Well Power Inc. (WPWR)

The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0405, up 2.27%, on 453,123 volume with 49 trades. The stock’s average daily volume over the past 60 days is 109,043, and its 52-week low/high is $0.03/$2.00.

Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.

The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.

Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer

Well Power Inc. Company Blog

Well Power Inc. News:

Well Power - Letter from President to Shareholders

Well Power Inc. to host second webinar on proprietory micro-refinery technology

Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program

Sibling Group Holdings, Inc. (SIBE)

The QualityStocks Daily Newsletter would like to spotlight Sibling Group Holdings, Inc. (SIBE). Today, Sibling Group Holdings, Inc. closed trading at $0.1359, up 0.22%, on 73,325 volume with 13 trades. The stock’s average daily volume over the past 60 days is 62,724, and its 52-week low/high is $0.04/$0.24.

Sibling Group Holdings, Inc. (SIBE) is enhancing and delivering 21st century learning with advanced technology and education management operations. Accessing funds from the public capital markets is part of the company’s unified strategy to accelerate the improvement of Pre-K, K-12 and post-secondary education around the world. Better educated children and adults, sustainable and cost effective instructional models, and reduced dependence on governmental funding are the end results.

Existing offerings include professional development for the teaching profession; educational technology, including classroom management tools; a comprehensive and flexible online curriculum; an aggregation platform for massive open online courses, and academic and skills credentialing. Investments are being made in specialized curriculum such as STEM (science, technology, engineering and math), ESL (english as a second language), SEL (social and emotional learning), and Special Ed aimed at supporting students with special needs and their teachers.

Sibling Group is acquiring various Ed-tech businesses and components with the goal of building the first complete solution for the delivery and management of educational content, and tracking educational results, in the digital media – from curriculum to course certification. The recent acquisition of Blended Schools Network (BSN), which serves over 160 school districts with 300,000 course enrollments and currently offers 212 different online courses, is a great example and has provided Sibling Group with extensive infrastructure and solid groundwork for growth in a rapidly growing industry.

IBIS Capital is forecasting fifteen-fold growth in the e-learning market over the next 10 years and has even suggested that under certain circumstances the transition to digital education may be quicker and more disruptive than ever observed in the media industry. With a strong, highly experienced management team, Sibling Group is in a unique position to continue expanding its portfolio through additional acquisitions and fundamental growth. Disclaimer

Sibling Group Holdings, Inc. Company Blog

Sibling Group Holdings, Inc. News:

Sibling Group Holdings, Inc. Interviewed by TheStockRadio.com

Sibling Group's Blended Schools Network Partners With BloomBoard, Inc. for Teacher Professional Development

Sibling Group to Acquire Urban Planet Mobile™ -- Leading Global Innovator of Educational Products

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $8.50, even with yesterday's close. The stock’s average daily volume over the past 60 days is 233, and its 52-week low/high is $5.508/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

VistaGen Receives Notice of Allowance for Canadian Patent, Further Expanding Stem Cell Technology Platform

VistaGen Announces Reverse Stock Split


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters







Penny Stock General

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251